Medical Oncology

, 30:567

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer

  • Sasmit Sarangi
  • Ambarish Pandey
  • Anne-Laure Papa
  • Poulomi Sengupta
  • Jawahar Kopparam
  • Ushashi Dadwal
  • Sudipta Basu
  • Shiladitya Sengupta
Short Communication

DOI: 10.1007/s12032-013-0567-y

Cite this article as:
Sarangi, S., Pandey, A., Papa, AL. et al. Med Oncol (2013) 30: 567. doi:10.1007/s12032-013-0567-y

Abstract

Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

Keywords

P2Y12 receptorCisplatinBreast cancerHIF1α

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sasmit Sarangi
    • 1
  • Ambarish Pandey
    • 1
    • 2
  • Anne-Laure Papa
    • 1
  • Poulomi Sengupta
    • 1
  • Jawahar Kopparam
    • 1
  • Ushashi Dadwal
    • 1
  • Sudipta Basu
    • 1
  • Shiladitya Sengupta
    • 1
  1. 1.Department of MedicineBrigham and Women’s HospitalCambridgeUSA
  2. 2.Department of MedicineUniversity of Southwestern Medical CenterDallasUSA